Mizuho Initiates Coverage On CRISPR Therapeutics with Buy Rating, Announces Price Target of $82
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Salim Syed has initiated coverage on CRISPR Therapeutics (NASDAQ:CRSP) with a Buy rating and a price target of $82.
September 27, 2023 | 8:50 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CRISPR Therapeutics has been initiated with a Buy rating by Mizuho, with a price target of $82.
The initiation of coverage by Mizuho with a Buy rating and a price target of $82 indicates a positive outlook for CRISPR Therapeutics. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100